Skip to main content
Premium Trial:

Request an Annual Quote

OraSure Stock Ticks Up on Rumor of Declined Quidel Acquisition Offer

NEW YORK – Diagnostics developer OraSure Technologies' stock on the Nasdaq rose as much as nearly 12 percent on heavy volume on Monday following a report that the firm had declined an acquisition offer from Quidel.

As reported by Street Insider, a source at OraSure claimed that Quidel made a bid to acquire the Bethlehem, Pennsylvania, immunoassay developer and microbiome testing services provider.

The story called the bid a "takeover approach" and said it was "rejected" by OraSure. The story also suggested that OraSure is evaluating starting a sales process after the bid.

On the news, OraSure's stock rose as high as $11.09 per share on Monday though the gains retreated during the day and closed up almost 3 percent at $10.20. Almost 4.8 million shares were traded during the day, compared to the average daily volume of 913,788.

On Tuesday, OraSure's shares were down a fraction of 1 percent at $10.14 in early morning trading.

Quidel's stock, meanwhile, was up 10 percent to $135.03 on the Nasdaq on Monday. In early trading Tuesday morning, its shares were down 2 percent at $132.07.

OraSure did not reply to a request for comment in time for publication. "We don't comment on M&A rumors," said Quidel's director of investor relations, Ruben Argueta, in an email.

Quidel closed the first quarter with $981.1 million in cash and cash equivalents on the books. During its fourth quarter and full-year earnings call in February, Quidel's CEO Douglas Bryant said, "We have cash and easy access to capital but are not compelled to acquire anything that isn't a great fit strategically."

OraSure received Emergency Use Authorization from the US Food and Drug Administration for a home-use rapid antigen assay to detect SARS-CoV-2 last month. In Q1, the firm reported a balance of $177.7 million in cash and cash equivalents.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.